Concomitant therapies for first-line Helicobacter pylori eradicatio

Phase 3

• Conditions: Condition 1: Gastric ulcer. Condition 2: Duodenal ulcer.; Gastric ulcer; Duodenal ulcer

• Registration Number: IRCT20170521034070N2
• Lead Sponsor: Sari University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients with peptic ulcer disease according to endoscopic findings
Presence of Helicobacter pylori is proven in gastric tissue according to pathologic assessment of gastric biopsy
No history of previous treatment for Helicobacter pylori

Exclusion Criteria

Breast feeding
History of gastrointestinal surgery
History of gastrointestinal malignancy
using anticoagulant drugs
using anti convulsion drugs
pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Helicobacter pylori eradication. Timepoint: Eight weeks after receiving the drugs, Helicobacter pylori eradication will be evaluated by Urea Breath test. Method of measurement: Urea Breath test.